Edition:
United States

Profile: Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

79.75CHF
8:25am EDT
Change (% chg)

CHF-0.05 (-0.06%)
Prev Close
CHF79.80
Open
CHF80.00
Day's High
CHF80.05
Day's Low
CHF79.40
Volume
21,547
Avg. Vol
65,529
52-wk High
CHF95.35
52-wk Low
CHF66.00

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The Company’s anti-infectives, including isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic, BAL30072 and the oncology compound, BAL101553 are in clinical phase I. The Company’s subsidiaries include Basilea Pharmaceutica China Ltd., Basilea Pharmaceuticals A/S, Basilea Pharma SAS, Basilea Pharmaceutica Deutschland GmbH, Basilea Pharmaceutica International Ltd., BPh Investitionen Ltd., Basilea Medical Ltd. and Basilea Pharmaceuticals Ltd.

Company Address

Basilea Pharmaceutica AG

Grenzacherstrasse 487
BASEL     4058
P: +4161.6061111
F: +4161.6061112

Company Web Links